Based on these results, it is recommended in the NCCN guidelines [38] that for postmenopausal HR‐positive/HER2‐negative breast cancer patients with PIK3CA mutation, the second‐line treatment of choice should be a combination therapy of alpelisib and fulvestrant (category 1). Here, ERBB2 is linked to breast cancer.